Meningitis B (MenB) Vaccine Availability in Quebec
DORVAL, QC, Feb. 25, 2014 /CNW/ - Novartis Pharmaceuticals Canada Inc.
("Novartis") would like to provide an update on the availability of
Bexsero®, in light of the tragic news of another Quebec adolescent
succumbing to meningitis B (MenB). Bexsero ®, a MenB vaccine indicated
to help protect children aged two months to 17 years of age, was
approved in December 2013 by Health Canada1. As of today, the vaccine is now available to Health Care
Novartis is working to ensure that the vaccine will be available
throughout Quebec, including in the area of the Saguenay where
prevalence of MenB disease is highest in Canada. We encourage parents
to talk to their doctors about MenB and Bexsero®.
Bexsero® is the first and only broad coverage vaccine to help protect individuals
from MenB disease who are at the greatest risk of infection, including
infants, toddlers and adolescents.2
Since 2003, Quebec has seen an increase of meningococcal disease caused
by MenB3. From 2009 to 2011, MenB was responsible for 61 per cent of all deaths
caused by meningococcal disease and accounted for 100 per cent of all
laboratory-confirmed cases that occurred among infants under one year
of age and 94 per cent of cases in individuals from 1 to 24 years old.3
Meningococcal disease caused by MenB is the most common cause of
meningococcal disease in Canada.2
1 BEXSERO™ Product Monograph. Novartis Pharmaceuticals Canada Inc.,
2 National Advisory Committee on Immunization. (2013) Update on the use
of Quadrivalent Conjugate
Meningococcal Vaccines. Canada Communicable Disease Report. January
2013; Vol. 39, ACS-1.
3 Gilca, R. et al. The Changing Epidemiology of Meningococcal Disease in
Quebec, Canada, 1991-2011: Potential Implications of Emergence of New
Strains. November 2012. Volume 7. Issue 11.
SOURCE: Novartis Pharmaceuticals Canada Inc.
For further information:
Novartis Pharma Communications